EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GUDCA drives colorectal cancer progression via ALKBH5-mediated m6A modification of ENO1 and glycolytic reprogramming

Ruirong Lin, Shangkun Jin, Weijin Yang, Jiarong Zhang, Jiantao Jiang, Wenmin Xiao, Yun Xie, Changhua Zhuo, Xiaopeng Wang

Frontiers in Pharmacology · 10.07.2026 · 17

DOI: 10.3389/fphar.2026.1791014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.07.2026. Verfasst von Ruirong Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Colorectal cancer (CRC) is the third most diagnosed malignancy worldwide, yet the mechanisms by which bile acids drive metabolic reprogramming remain unclear. This study investigates whether glycoursodeoxycholic acid (GUDCA) promotes CRC progression through mA epitranscriptomic regulation.

Methods

Serum bile acids were profiled in 106 CRC patients and 106 controls by UHPLC-MS/MS. Cellular phenotypes were assessed by CCK-8, colony formation, and xenograft models. mA modification was mapped by meRIP-seq and validated by meRIP-qPCR. Glycolytic function was measured by lactate production, glucose uptake, and ECAR. FXR binding to the ALKBH5 promoter was assessed by luciferase assay and ChIP-qPCR. Clinical correlations were analyzed in 25 CRC patients undergoing 1 F-FDG-PET.

Results

GUDCA was the most significantly elevated bile acid in CRC patients and independently predicted poor survival (HR = 3.28, p < 0.001). GUDCA promoted CRC cell proliferation and xenograft tumor growth. Mechanistically, GUDCA antagonized FXR to suppress ALKBH5 transcription, elevating mA modification of ENO1 mRNA and enhancing its translation efficiency. ALKBH5 deficiency drove glycolytic reprogramming and mTORC1 activation. ENO1 silencing abolished GUDCA-induced glycolytic enhancement. Serum GUDCA positively correlated with 1 F-FDG-PET SUVmax (r = 0.68, p < 0.001). Low ALKBH5 expression correlated with poor patient survival.

Conclusion

GUDCA functions as an oncometabolite that drives CRC progression via the GUDCA–FXR–ALKBH5–ENO1 axis, establishing a feed-forward metabolic circuit linking bile acid signaling to mA-mediated glycolytic reprogramming. These findings identify GUDCA and ALKBH5 as potential therapeutic vulnerabilities in CRC.

Schlagwörter

Stichwörter der Autor:innen

ALKBH5ENO1GUDCAcolorectal cancerglycolysism6A modification

Autor:innen und Institutionen

  • Department of Thoracic Oncology Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • College of Chemistry, Fuzhou University, Fuzhou, China.
  • Department of Colorectal Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Department of Gastric Surgery Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.

Zitieren

APA

Lin, R., Jin, S., Yang, W., Zhang, J., Jiang, J., Xiao, W., Xie, Y., Zhuo, C., & Wang, X. (2026). GUDCA drives colorectal cancer progression via ALKBH5-mediated m6A modification of ENO1 and glycolytic reprogramming. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1791014

Vancouver

Lin R, Jin S, Yang W, Zhang J, Jiang J, Xiao W, et al. GUDCA drives colorectal cancer progression via ALKBH5-mediated m6A modification of ENO1 and glycolytic reprogramming. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1791014

BibTeX
@article{Lin2026,
  author = {Lin, Ruirong and Jin, Shangkun and Yang, Weijin and Zhang, Jiarong and Jiang, Jiantao and Xiao, Wenmin and Xie, Yun and Zhuo, Changhua and Wang, Xiaopeng},
  title = {GUDCA drives colorectal cancer progression via ALKBH5-mediated m6A modification of ENO1 and glycolytic reprogramming},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1791014}
}
Kostenlos starten →